These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 12412207)

  • 21. Successful long-term thalidomide therapy for discoid lupus erythematosus-lichen planus overlap syndrome.
    Zhang L; Au S; Aronson IK
    Dermatol Online J; 2014 Oct; 20(10):. PubMed ID: 25526013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells.
    Deng L; Ding W; Granstein RD
    J Invest Dermatol; 2003 Nov; 121(5):1060-5. PubMed ID: 14708607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.
    Breitkreutz I; Anderson KC
    Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):973-85. PubMed ID: 18624684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on immunosuppressive therapy.
    Singer NG; McCune WJ
    Curr Opin Rheumatol; 1998 May; 10(3):169-73. PubMed ID: 9608317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Thalidomide in Discoid Lupus Erythematosus: Insights into the Molecular Mechanisms.
    Domingo S; Solé C; Moliné T; Ferrer B; Ordi-Ros J; Cortés-Hernández J
    Dermatology; 2020; 236(5):467-476. PubMed ID: 32659758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thalidomide in the treatment of refractory rheumatoid arthritis.
    Keesal N; Wasserman MJ; Bookman A; Lapp V; Weber DA; Keystone EC
    J Rheumatol; 1999 Nov; 26(11):2344-7. PubMed ID: 10555888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Thalidomide and thrombosis].
    Flageul B; Wallach D; Cavelier-Balloy B; Bachelez H; Carsuzaa F; Dubertret L
    Ann Dermatol Venereol; 2000 Feb; 127(2):171-4. PubMed ID: 10739975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current use of thalidomide].
    Revuz J
    Ann Dermatol Venereol; 1990; 117(4):313-21. PubMed ID: 2195968
    [No Abstract]   [Full Text] [Related]  

  • 29. Thalidomide in gastrointestinal disorders.
    Bousvaros A; Mueller B
    Drugs; 2001; 61(6):777-87. PubMed ID: 11398909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update on therapy--thalidomide in the treatment of lupus.
    Karim MY; Ruiz-Irastorza G; Khamashta MA; Hughes GR
    Lupus; 2001; 10(3):188-92. PubMed ID: 11315350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thalidomide: dermatological indications, mechanisms of action and side-effects.
    Wu JJ; Huang DB; Pang KR; Hsu S; Tyring SK
    Br J Dermatol; 2005 Aug; 153(2):254-73. PubMed ID: 16086735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Thalidomide: new uses for an old drug].
    Wu KL; Sonneveld P
    Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1438-41. PubMed ID: 12190008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Theoretical basis for the activity of thalidomide.
    Meierhofer C; Dunzendorfer S; Wiedermann CJ
    BioDrugs; 2001; 15(10):681-703. PubMed ID: 11604049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dermatologic and nondermatologic uses of thalidomide.
    Nasca MR; Micali G; Cheigh NH; West LE; West DP
    Ann Pharmacother; 2003 Sep; 37(9):1307-20. PubMed ID: 12921515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exacerbation of psoriasis by thalidomide in Behçet's syndrome.
    Dobson CM; Parslew RA
    Br J Dermatol; 2003 Aug; 149(2):432-3. PubMed ID: 12932265
    [No Abstract]   [Full Text] [Related]  

  • 36. Potential mechanisms of benefit with thalidomide in chronic heart failure.
    Aukrust P; Yndestad A; Damås JK; Ueland T; Øie E; Gullestad L
    Am J Cardiovasc Drugs; 2007; 7(2):127-34. PubMed ID: 17503883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thalidomide: an old drug with new clinical applications.
    Laffitte E; Revuz J
    Expert Opin Drug Saf; 2004 Jan; 3(1):47-56. PubMed ID: 14680461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis.
    Tramontana JM; Utaipat U; Molloy A; Akarasewi P; Burroughs M; Makonkawkeyoon S; Johnson B; Klausner JD; Rom W; Kaplan G
    Mol Med; 1995 May; 1(4):384-97. PubMed ID: 8521296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thalidomide has both anti-inflammatory and regulatory effects in Behcet's disease.
    Direskeneli H; Ergun T; Yavuz S; Hamuryudan V; Eksioglu-Demiralp E
    Clin Rheumatol; 2008 Mar; 27(3):373-5. PubMed ID: 18034203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic vasculitis and the gut.
    Hatemi I; Hatemi G; Çelik AF
    Curr Opin Rheumatol; 2017 Jan; 29(1):33-38. PubMed ID: 27684357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.